← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

NeuroOne Medical Technologies Corporation (NMTC) 10-Year Financial Performance & Capital Metrics

NMTC • • Industrial / General
HealthcareMedical DevicesNeurological & Neurostimulation DevicesNeurological Monitoring & Diagnostics
AboutNeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.Show more
  • Revenue $12M +250.4%
  • EBITDA -$4M +65.9%
  • Net Income -$4M +70.7%
  • EPS (Diluted) -0.09 +80.4%
  • Gross Margin 67.3% +115.2%
  • EBITDA Margin -32.77% +90.3%
  • Operating Margin -34.94% +89.9%
  • Net Margin -29.8% +91.6%
  • ROE -91.34% +73.8%
  • ROIC -1621.09% +33.3%
  • Debt/Equity 0.04 -88.1%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 44.4%
  • ✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 50.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y163.77%
5Y44.41%
3Y313.45%
TTM163.47%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM70.73%

EPS CAGR

10Y-
5Y-
3Y-
TTM-800%

ROCE

10Y Avg-242.78%
5Y Avg-163.58%
3Y Avg-157.69%
Latest-72.62%

Peer Comparison

Neurological Monitoring & Diagnostics
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
AMIXAutonomix Medical, Inc. Common Stock3.59M0.52-0.08-258.98%
CBLLCeriBell, Inc.847.27M22.84-6.7444.71%-63.35%-31.97%0.11
NMTCNeuroOne Medical Technologies Corporation45.32M0.90-9.99250.35%-39.63%-50.98%0.04
CLPTClearPoint Neuro, Inc.435.81M14.65-20.9331.04%-67.4%-145.77%0.14

Profit & Loss

Dec 2016Dec 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Sales/Revenue+00001.93M178.15K171.17K1.95M3.45M12.1M
Revenue Growth %-1%-----0.91%-0.04%10.41%0.77%2.5%
Cost of Goods Sold+7.74K17.63K21.67K27.57K70.55K275.89K241.96K1.5M2.37M3.96M
COGS % of Revenue----0.04%1.55%1.41%0.77%0.69%0.33%
Gross Profit+-7.74K-17.63K-21.67K-27.57K1.86M-97.75K-70.79K456.52K1.08M8.14M
Gross Margin %----0.96%-0.55%-0.41%0.23%0.31%0.67%
Gross Profit Growth %-11.43%-1.28%-0.23%-0.27%68.32%-1.05%0.28%7.45%1.37%6.54%
Operating Expenses+32.61K3.07M3.19M5.81M6.76M10.12M9.96M12.41M12.97M12.37M
OpEx % of Revenue----3.51%56.81%58.19%6.36%3.76%1.02%
Selling, General & Admin32.61K2.34M3.54M4.28M4.75M6.26M6.98M6.93M7.9M7.38M
SG&A % of Revenue----2.47%35.14%40.77%3.55%2.29%0.61%
Research & Development0735.33K951.06K1.53M2.08M3.93M4.93M6.94M5.07M4.98M
R&D % of Revenue----1.08%22.03%28.8%3.55%1.47%0.41%
Other Operating Expenses00-1.3M0-70.55K-64.81K-1.95M-1.46M00
Operating Income+-32.61K-3.07M-3.21M-5.81M-4.9M-10.22M-10.03M-11.96M-11.89M-4.23M
Operating Margin %-----2.54%-57.36%-58.6%-6.12%-3.44%-0.35%
Operating Income Growth %-0.05%-93.21%-0.05%-0.81%0.16%-1.08%0.02%-0.19%0.01%0.64%
EBITDA+-24.87K-3.05M-3.19M-5.79M-4.83M-10.07M-9.91M-11.76M-11.64M-3.96M
EBITDA Margin %-----2.51%-56.53%-57.91%-6.02%-3.37%-0.33%
EBITDA Growth %-0.07%-121.82%-0.04%-0.81%0.16%-1.08%0.02%-0.19%0.01%0.66%
D&A (Non-Cash Add-back)7.74K17.63K21.67K27.57K70.55K147.13K118.62K199.27K246.79K261.68K
EBIT-189.73K-3.07M-4.17M-5.81M-4.9M-9.95M-10.03M-11.96M-12.09M-3.27M
Net Interest Income+0000-7.52M-3.05K00-228.99K0
Interest Income0000000000
Interest Expense01.4M0284.56K7.52M3.05K00228.99K0
Other Income/Expense156.71K-1.99M-2.66M-967.77K-8.74M270.04K31.15K95.76K-430.9K621.1K
Pretax Income+-32.61K-5.06M-6.83M-6.78M-13.64M-9.95M-10M-11.86M-12.32M-3.61M
Pretax Margin %-----7.08%-55.84%-58.42%-6.07%-3.57%-0.3%
Income Tax+15.16K030000000
Effective Tax Rate %1.46%1%1%1%1%1%1%1%1%1%
Net Income+-47.77K-5.06M-6.83M-6.78M-13.64M-9.95M-10M-11.86M-12.32M-3.61M
Net Margin %-----7.08%-55.84%-58.42%-6.07%-3.57%-0.3%
Net Income Growth %0.24%-104.88%-0.35%0.01%-1.01%0.27%-0.01%-0.19%-0.04%0.71%
Net Income (Continuing)-284.97K-5.06M-6.83M-6.78M-13.64M-9.95M-10M-11.86M-12.32M-3.61M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.03-2.30-2.43-1.72-2.52-0.93-0.63-0.65-0.46-0.09
EPS Growth %0.24%-80.27%-0.06%0.29%-0.47%0.63%0.32%-0.03%0.29%0.8%
EPS (Basic)-0.03-2.30-2.43-1.72-2.52-0.93-0.63-0.65-0.46-0.09
Diluted Shares Outstanding1.69M2.2M2.81M3.95M5.42M10.7M16M18.12M26.76M40.15M
Basic Shares Outstanding1.69M2.2M2.81M3.95M5.42M10.7M16M18.12M26.76M40.15M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Current Assets+576.04K33.61K18.64K301.75K4.16M7.29M12.18M7.31M4.63M10.23M
Cash & Short-Term Investments522.22K26.47K13.26K260.75K4.04M6.9M11.14M5.32M1.46M6.57M
Cash Only522.22K26.47K13.26K260.75K4.04M6.9M8.16M5.32M1.46M6.57M
Short-Term Investments0000002.98M000
Accounts Receivable0000048.34K33.24K0176.64K1.26M
Days Sales Outstanding-----99.0370.87-18.6738.16
Inventory0000098.29K704.54K1.73M2.64M2.23M
Days Inventory Outstanding-----130.031.06K421.31405.27205.44
Other Current Assets000060192.93K00142.63K22.92K
Total Non-Current Assets+180.89K216.37K200.08K230.86K604.76K646.48K646.85K784.39K739.01K559.36K
Property, Plant & Equipment00052.03K448.24K512.28K534.95K694.81K671.75K514.42K
Fixed Asset Turnover----4.30x0.35x0.32x2.81x5.14x23.52x
Goodwill0000000000
Intangible Assets180.89K216.37K200.08K178.84K156.52K134.21K111.89K89.58K67.26K44.95K
Long-Term Investments0000000000
Other Non-Current Assets0000000000
Total Assets+756.93K249.99K218.72K532.62K4.76M7.94M12.82M8.1M5.37M10.79M
Asset Turnover----0.40x0.02x0.01x0.24x0.64x1.12x
Asset Growth %410.82%-0.67%-0.13%1.44%7.94%0.67%0.62%-0.37%-0.34%1.01%
Total Current Liabilities+677.19K3.91M3.8M1.77M2.36M1.18M3.1M1.79M2.21M2.3M
Accounts Payable22.36K0221.24K1.15M762.54K528.83K927.66K685.1K1.03M1.01M
Days Payables Outstanding1.05K-3.73K15.26K3.94K699.621.4K167.16158.2893.21
Short-Term Debt275.2K2.42M1.68M01.01M00000
Deferred Revenue (Current)73.76K00073.43K8.62K1000K000
Other Current Liabilities351.38K1.26M512.39K50.4K166.3K00059.95K1.44K
Current Ratio0.85x0.01x0.00x0.17x1.76x6.17x3.93x4.08x2.09x4.44x
Quick Ratio0.85x0.01x0.00x0.17x1.76x6.09x3.70x3.12x0.90x3.47x
Cash Conversion Cycle------470.56-265.71-265.65150.39
Total Non-Current Liabilities+345.96K1.38M817.15K0337.66K202.9K119.56K55.28K2.33M1.41M
Long-Term Debt0000000000
Capital Lease Obligations0000254.33K202.9K119.56K55.28K194.39K143.15K
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities345.96K1.38M817.15K083.33K0002.14M1.27M
Total Liabilities1.02M5.29M4.61M1.77M2.69M1.38M3.22M1.85M4.55M3.71M
Total Debt+275.2K2.42M1.68M01.32M315.67K202.9K184.4K260.16K266.81K
Net Debt-247.02K2.39M1.66M-260.75K-2.72M-6.59M-7.96M-5.14M-1.2M-6.3M
Debt / Equity----0.64x0.05x0.02x0.03x0.32x0.04x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage--2.20x--20.43x-0.65x-3346.94x---51.91x-
Total Equity+-266.22K-5.04M-4.4M-1.24M2.07M6.55M9.6M6.25M822.01K7.07M
Equity Growth %-2.27%-17.92%0.13%0.72%2.67%2.17%0.47%-0.35%-0.87%7.6%
Book Value per Share-0.16-2.29-1.57-0.310.380.610.600.340.030.18
Total Shareholders' Equity-266.22K-5.04M-4.4M-1.24M2.07M6.55M9.6M6.25M822.01K7.07M
Common Stock317.87K9.66K13.49K22.18K12.01K16.22K23.93K30.82K50.01K
Retained Earnings-266.37K-5.32M-10.46M-17.24M-30.88M-40.83M-50.83M-62.69M-75M-78.61M
Treasury Stock0000000000
Accumulated OCI0000000000
Minority Interest0000000000

Cash Flow

Dec 2016Dec 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Cash from Operations+-21.11K-2.11M-2.83M-5.4M-3.43M-8.6M-7.52M-12.89M-11.01M-2.84M
Operating CF Margin %-----1.78%-48.29%-43.93%-6.6%-3.19%-0.23%
Operating CF Growth %0.3%-98.88%-0.34%-0.91%0.37%-1.51%0.13%-0.71%0.15%0.74%
Net Income-47.77K-5.06M-6.76M-6.78M-13.64M-9.95M-10M-11.86M-12.32M-3.61M
Depreciation & Amortization7.74K17.63K20.56K27.57K47.61K80.75K118.62K199.27K246.79K261.68K
Stock-Based Compensation076.79K486.12K491.75K1.84M1.79M947.21K1.11M1.34M1.26M
Deferred Taxes0590.97K0683.21K2.02M-85.31K-11.47K000
Other Non-Cash Items15.62K2M3.42M284.56K6.74M69.44K212.16K96.4K669.61K-758.18K
Working Capital Changes11.05K859.89K1.77K-101.88K-429.56K-512.73K1.21M-2.43M-954.61K0
Change in Receivables00000-48.34K15.1K33.24K-176.64K-1.09M
Change in Inventory00000-98.29K-606.25K-1.02M-908.47K10K
Change in Payables11.51K00770.61K-269.6K-350.31K515.44K-247.19K66.99K239.98K
Cash from Investing+0-91.71K-146.71K-123.35K-122.43K-67.08K-3.24M2.65M-120.2K-81.74K
Capital Expenditures0-91.71K0-123.35K-122.43K-67.08K-275.23K-384.12K-120.2K-81.74K
CapEx % of Revenue----0.06%0.38%1.61%0.2%0.03%0.01%
Acquisitions----------
Investments----------
Other Investing0-91.71K-146.71K-65K00-2.97M7.5K00
Cash from Financing+21.11K1.7M2.92M5.77M7.32M11.53M12.02M7.4M7.27M141.42K
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing21.11K749.9K2.92M1.49M-1.51M2.71M-1.33M-1.07M1.48M141.42K
Net Change in Cash----------
Free Cash Flow+-21.11K-2.2M-2.83M-5.52M-3.55M-8.67M-7.79M-13.27M-11.13M-2.92M
FCF Margin %-----1.84%-48.67%-45.54%-6.8%-3.22%-0.24%
FCF Growth %0.3%-103.23%-0.29%-0.95%0.36%-1.44%0.1%-0.7%0.16%0.74%
FCF per Share-0.01-1.00-1.01-1.40-0.66-0.81-0.49-0.73-0.42-0.07
FCF Conversion (FCF/Net Income)0.44x0.42x0.41x0.80x0.25x0.86x0.75x1.09x0.89x0.79x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-----3292.36%-230.81%-123.77%-149.61%-348.39%-91.34%
Return on Invested Capital (ROIC)-------931.56%-650.16%-2431.11%-1621.09%
Gross Margin----96.34%-54.87%-41.36%23.38%31.27%67.3%
Net Margin-----708%-5584.28%-5841.95%-607.42%-356.74%-29.8%
Debt / Equity----0.64x0.05x0.02x0.03x0.32x0.04x
Interest Coverage--2.20x--20.43x-0.65x-3346.94x---51.91x-
FCF Conversion0.44x0.42x0.41x0.80x0.25x0.86x0.75x1.09x0.89x0.79x
Revenue Growth-100%-----90.75%-3.92%1040.65%76.86%250.35%

Frequently Asked Questions

Growth & Financials

NeuroOne Medical Technologies Corporation (NMTC) reported $9.1M in revenue for fiscal year 2025. This represents a 987706% increase from $0.0M in 2012.

NeuroOne Medical Technologies Corporation (NMTC) grew revenue by 250.4% over the past year. This is strong growth.

NeuroOne Medical Technologies Corporation (NMTC) reported a net loss of $3.6M for fiscal year 2025.

Dividend & Returns

NeuroOne Medical Technologies Corporation (NMTC) has a return on equity (ROE) of -91.3%. Negative ROE indicates the company is unprofitable.

NeuroOne Medical Technologies Corporation (NMTC) had negative free cash flow of $2.9M in fiscal year 2025, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.